CytoSen Therapeutics, Inc.
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From CytoSen Therapeutics, Inc.
Kiadis And Sanofi Sign Natural Killer Cell Therapy Pact
Sanofi is paying €17.5m upfront to combine a preclinical NK cell product with its anti-CD38 antibody Sarclisa and develop a multiple myeloma drug that potentially may prove more effective than J&J's Darzalex, Kiadis's CEO tells Scrip.
Re-Focused Kiadis Preps Trials With Natural Killer Cells
Kiadis Pharma’s CEO says its processed natural kill cell therapies can improve hematopoietic stem cell transplants and also treat resurgent leukemia.
Kiadis Crushed By EMA Rejection Of T-Cell Therapy
The Dutch company's dataset on its stem cell transplant adjunct ATIR101 is not enough to satisfy European regulators as the standard of care in post-transplant patients has changed since the original filing.
Tech Transfer Roundup: UCSD Sees Many Benefits From Entrepreneurs In Residence Program
Asterias obtains IP estate related to ischemic stroke from University of California. Plus Apeiron, Qualigen, Biovaxys and AbbVie turn to academic partners for early-stage cancer assets.
Company Information
- Industry
- Biotechnology
- Pharmaceuticals
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice